Cytokinetics Inc. (CYTK)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.56 (+1.11%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Cytokinetics Inc. (CYTK)
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Key Insights

Critical company metrics and information

  • Share Price

    $50.96

  • Market Cap

    $6.01 Billion

  • Total Outstanding Shares

    118.01 Million Shares

  • Total Employees

    564

  • Dividend

    No dividend

  • IPO Date

    April 29, 2004

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.cytokinetics.com

Historical Stock Splits

If you bought 1 share of CYTK before June 25, 2013, you'd have 0.17 shares today.
Execution DateSplit Amount
June 25, 20131-for-6 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-52.70 Million
Net Cash Flow From Investing Activities$-745.37 Million
Net Cash Flow From Financing Activities$1.10 Billion
Net Cash Flow From Operating Activities, Continuing$-404.36 Million
Net Cash Flow From Investing Activities, Continuing$-745.37 Million
Exchange Gains/Losses$103000.00
Net Cash Flow From Operating Activities$-404.36 Million
Net Cash Flow$-52.80 Million
Net Cash Flow From Financing Activities, Continuing$1.10 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Nonoperating Income/Loss$44.11 Million
Interest Expense, Operating$35.93 Million
Benefits Costs and Expenses$275.05 Million
Research and Development$330.75 Million
Income/Loss From Continuing Operations Before Tax$-415.39 Million
Operating Expenses$527.85 Million
Diluted Average Shares$329707.00
Net Income/Loss Available To Common Stockholders, Basic$-576.40 Million
Diluted Earnings Per Share$5.38
Income/Loss From Continuing Operations After Tax$-576.40 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-576.40 Million
Preferred Stock Dividends And Other Adjustments$0.00
Operating Income/Loss$-524.63 Million
Costs And Expenses$546.73 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$-576.40 Million
Revenues$3.22 Million
Basic Average Shares$110790.00
Other Operating Expenses$197.09 Million
Basic Earnings Per Share$5.38

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Accounts Payable$11.58 Million
Liabilities And Equity$1.44 Billion
Other Non-current Liabilities$720.21 Million
Wages$27.88 Million
Equity$-13.91 Million
Current Assets$1.02 Billion
Noncurrent Assets$417.46 Million
Noncurrent Liabilities$1.34 Billion
Liabilities$1.45 Billion
Other Current Liabilities$70.35 Million
Equity Attributable To Noncontrolling Interest$0.00
Fixed Assets$64.22 Million
Assets$1.44 Billion
Equity Attributable To Parent$-13.91 Million
Cash$1.30 Billion
Long-term Debt$619.95 Million
Current Liabilities$109.81 Million
Other Non-current Assets$353.24 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.